Editorially independent. Revenue never influences our rankings. · Updated weekly · Last reviewed June 9, 2026
Clinical Research

Clinical Research

Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.

Detailed clinical research summaries for the GLP-1 trial program. Each page distills a major trial — STEP, SURMOUNT, SELECT, FLOW — and its clinical implications.

STEP trials (semaglutide)

STEP-1, STEP-4, STEP-HFpEF. Weight management foundation.

SURMOUNT trials (tirzepatide)

SURMOUNT-1, SURMOUNT-OSA. Tirzepatide foundation + OSA approval.

SELECT — CV outcomes

20% MACE reduction in obesity + CVD without diabetes.

FLOW — kidney outcomes

24% reduction in major kidney events in T2D + CKD.

Mechanism of GLP-1

Pharmacology beyond "appetite suppressant."

Contraindications

MTC, MEN-2, pregnancy, severe GI disease.

Drug interactions

Insulin, anesthesia, oral contraceptives, pregnancy planning.